Australia - engelsk - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - damoctocog alfa pegol, quantity: 2000 iu - injection, powder for - excipient ingredients: glycine; histidine; sucrose; calcium chloride dihydrate; sodium chloride; polysorbate 80 - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - damoctocog alfa pegol, quantity: 1000 iu - injection, powder for - excipient ingredients: polysorbate 80; calcium chloride dihydrate; glycine; sodium chloride; sucrose; histidine - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - damoctocog alfa pegol, quantity: 250 iu - injection, powder for - excipient ingredients: polysorbate 80; sucrose; glycine; calcium chloride dihydrate; histidine; sodium chloride - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - damoctocog alfa pegol, quantity: 3000 iu - injection, powder for - excipient ingredients: calcium chloride dihydrate; sucrose; sodium chloride; glycine; histidine; polysorbate 80 - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - damoctocog alfa pegol, quantity: 500 iu - injection, powder for - excipient ingredients: sucrose; calcium chloride dihydrate; polysorbate 80; glycine; sodium chloride; histidine - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

bayer ag - damoctocog alfa pegol - hemofilja a - sustanzi kontra l-emorraġija - kura u profilassi ta ' fsada f'pazjenti li kienu kkurati qabel ≥ 12-il sena bl-emofilja a (nuqqas konġenitali tal-fattur viii).

Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

bayer ag - damoctocog alfa pegol - hemofilie a - antihemoragika - léčba a profylaxe krvácení u dříve léčených pacientů ve věku ≥ 12 let věku s hemofilií a (vrozený nedostatek faktoru viii).

Den europeiske union - dansk - EMA (European Medicines Agency)

bayer ag - damoctocog alfa pegol - hemophilia a - antihemorrhagics - behandling og profylakse af blødning hos tidligere behandlede patienter ≥ 12 år med hæmofili a (medfødt faktor viii-mangel).

Den europeiske union - tysk - EMA (European Medicines Agency)

bayer ag - damoctocog alfa pegol - hämophilie a - antihämorrhagika - behandlung und prophylaxe von blutungen bei zuvor behandelten patienten ≥ 12 jahren mit hämophilie a (angeborener faktor viii-mangel).

Den europeiske union - nederlandsk - EMA (European Medicines Agency)

bayer ag - damoctocog alfa pegol - hemophilia a - antihemorragica - behandeling en profylaxe van bloedingen in de eerder behandelde patiënten ≥ 12 jaar en ouder met hemofilie a (aangeboren factor viii-deficiëntie).